Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.

By J. Bonner, P. Harari, J. Giralt, N. Azarnia, D. Shin, R. Cohen, Christopher U. Jones, R. Sur, D. Raben, J. Jassem and 7 more. New England Journal of Medicine, 2006

5,083 citations recorded by the source corpus.

Subfields: Otorhinolaryngology, Pulmonary and Respiratory Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/9d44b115da084ac735294a9384636b74b50def7c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Otorhinolaryngology

1. A. Forastiere

In Pulmonary and Respiratory Medicine

1. Carlos L. Arteaga
2. J. Engelman
3. J. Chmielecki
4. William Pao
5. C. Der
6. P. Roberts

In Surgery

1. A. Ades
2. N. Welton
3. J. Engelman
4. Georgia Salanti
5. Ian R. White
6. Gerta Rücker

Citations in the corpus

• Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. (2013, positive): “A randomized trial comparing RT with or without cetuximab in patients with locally advanced, stage III or IV head and neck cancer showed significantly improved overall and locoregional failure-free survival (a composite end point) but no difference in distant metastasis.(13) Locoregional control was”
• Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer (2007, background): “one of its major drawbacks is the associated risk of anaphylactic reactions during cetuximab infusion (Cunningham et al., 2004; Bonner et al., 2006).”
• Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves (2012, methodology): “Illustration The illustrative example uses KM curves, reproduced in Figure 1, on locoregional control events in head and neck cancer [12].”
• An update on larynx cancer (2017, background): “was significantly more pronounced for oropharyngeal cancer than for laryngeal cancer in a subset analysis.(82) There is currently no evidence to support that concurrent cetuximab is superior to concurrent platinum-based therapy.”
• Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer (2010, background): “The antibody has been US Food and Drug Administration (FDA) approved for the treatment of colorectal and head and neck cancer”
• Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. (2008, neutral): “Age, median (range), y 55 (25-83) 55 ( 31-88 )”
• Normal tissue reactions to radiotherapy (2009, neutral): “The use of concurrent chemotherapy has become standard practice for a number of cancers, and the addition of new, molecularly targeted agents in combination with radiotherapy is promising to improve cure rates furthe”